Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles?

References

• ASHLEY, A. L., and MCGINITY, J. W., 1988, Degradation of D,L-polylactic acid by certain hydrolase enzymes. Pharmaceutical Research, 5, S243.
   Google Scholar
• BENOIT, J. P., CouaTEILLE, F., and THIES, C., 1986, A physicochemical study of the morphology of progesterone-loaded poly(n,L-lactide) microspheres. International Journal of Pharmacology, 29, 95–102.
   Google Scholar
• BODMEIER, R., and MCGINITY, J. W., 1988, Solvent selection in the preparation of poly(D,L-lactide) microspheres by the solvent evaporation method. International Journal of Pharmacology, 43, 179–186.
   Web of Science ®Google Scholar
• BRATTSAND, R., KALLsTaiim, L., NILSSON, E., RYRFELDT, A., and TöNNESSON, M., 1982, The lung disposition of budesonide in guinea-pig and rat. European Journal of Respiratory Diseases, 63, 263.
   Google Scholar
• CHA, Y., and PITT, C. G., 1988, A one week subdermal delivery system for L-Methadone based on biodegradable microcapsules. Journal of Controlled Release, 7,69–78.
   Google Scholar
• CHAWLA, A. S., and CHANG, T. M. S., 1985–86. In vivo degradation of poly(lactic acid) of different molecular weights. Biomaterials, Medical Devices and Artificial Organs, 13, 153–162.
   Google Scholar
• COWSAR, D. R., TICE, T. R., GILLEY, R. M., and ENGLISH, J. P., 1985, Poly(lactide-co-glycolide) microcapsules for controlled release of steroids. Methods in Enzymology, 112, 101–116.
   PubMedGoogle Scholar
• HARMSEN, H. G., MUGGENBURG, B. A., SNIPES, M. B., and BICE, D. E., 1985, The role of macrophages in particle translocation from lungs to lymph nodes. Science, 230, 1277–1280.
   PubMedGoogle Scholar
• HOLLAND, S. J., and TIGHE, B. J., 1986, Polymers as biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems. Journal of Controlled Release, 4,155–180.
   Google Scholar
• HUTCHINsoN, F. G., and FURR, B. J. A., 1987, Biodegradable carriers for the sustained release of polypeptides. Trends in Biotechnology, 5, 102–106.
   Google Scholar
• JONES, G. J., 1982, Clearance of inhaled particles from the alveoli. Aerosols and the Lung, edited by S. W. Clarke and D. Pavia (Butterworths, New York), pp. 170–190.
   Google Scholar
• KRAUSE, H. J., 1984, Dissertation, Minster. Herstellung und Charakterisierung bioab- baubarer Nanopartikel und Nanokapseln.
   Google Scholar
• LEVY, G., and HAYES, B. A., 1960, Physicochemical basis of the buffered acetylsalicylic controversy. New England Journal of Medicine, 262, 1053–1071.
   PubMedGoogle Scholar
• MAKING, K., ARAKAWA, M., and KONDO, T., 1985, Preparation and in vitro degradation properties of polylactide microcapsules. Chemical and Pharmaceutical Bulletin, 33, 1195–1201.
   PubMedGoogle Scholar
• MAKINO, K.,OnsxtmA, H., and KONDO, T., 1987, Effects of plasma proteins on degradation properties of poly(L-lactide) microcapsules. Pharmaceutical Research, 4,62–65.
   PubMedGoogle Scholar
• MAULDING, H. V., TICE, T. R., COWSAR, D. R., FONG, J. W., PEARSON, J. E., and NAZARENO, J. P., 1986, Biodegradable microcapsules: acceleration of polymeric excipient hydro-lytic rate by incorporation of a basic medicament. Journal of Controlled Release, 3, 103–117.
   Google Scholar
• MOSER, U., 1983, Obstruktive Atemwegserkrankungen und ihre medikamentöse Therapie. Deutsche Apotheker Zeitung, 123, 2191–2199.
   Google Scholar
• OGAWA, Y., OKADA, H., YAMAMOTO, M., and SHIMAMOTO, T., 1988, In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lacticiglycolic) acids and in vivo degradation of these polymers. Chemical and Pharmaceutical Bulletin, 36, 2576–2581.
   PubMedGoogle Scholar
• PEDERSEN, S., STEFFENSEN, G., EKMAN, I., TöNNESSON, M., and BORGA, A., 1987, Pharmaco-kinetics of budesonide in children with asthma. European Journal of Clinical Pharma-cology, 31, 579–582.
   PubMedGoogle Scholar
• PHILIPSON, K., FALK, R., and CAMNER, P., 1985, Long-term lung clearance in humans studied with Teflon particles labeled with chromium-51. Experimental Lung Research, 9, 31–42.
   PubMedGoogle Scholar
• ROHDEWALD, P., VON EIFF, M., and WORTHWEIN, G., 1990, Aktivierung von Beclometh-asondipropionat im Bronchliasekret sowie Rezeptoraffinitat und Löslichkeit inhalativ angewandter Glukokortikoide. Atemwegs und Lungenkrankheiten, 16, 79–84.
   Google Scholar
• SCIARRA, J., 1966, International Encyclopaedia of Pressurized Packing (Pergamon Press, Oxford).
   Google Scholar
• TSAI, D. C., HOWARD, S. A., HOGAN, T. F., MALANGA, C. J., KANDZARI, S. J., and MA, J. K. H., 1986, Preparation and in vitro evaluation of polylactic acid-mitomycin C microcapsules. Journal of Microencapsulation, 3,181–193.
   PubMedGoogle Scholar
• TSE TED, C. S., and BERNSTEIN, I. L., 1984, Corticoid aerosols in the treatment of asthma. Pharmacotherapy, 4,334–342.
   PubMedGoogle Scholar
• WADA, R., HYON, S. H., and IKADA, Y., 1988, Lactic acid oligomer microspheres containing an anticancer agent for selective lymphatic delivery. Journal of Bioactive Compatible Polymers, 3, 126–136.
   Google Scholar
• WAKIYAMA, N., JuNt, K., and NAKANO, M., 1982, Influence of physicochemical properties of polylactic acid on the characteristics and in vitro release patterns of polylactic acid microspheres containing local anesthetics. Chemical and Pharmaceutical Bulletin, 30, 2621–2628.
   PubMedGoogle Scholar
• WICHERT, B., and ROHDEWALD, P., 1990, A new method for the preparation of drug containing polylactic acid microparticles without using organic solvents. Journal of Controlled Release, 14, 269–283.
   Web of Science ®Google Scholar
• WILLIAMS, D. F., 1981, Enzyme hydrolysis of polylactic acid. Engineering in Medicine, 10, 5–7.
   Google Scholar
• WOODWARD, S. C., BREWER, P. S., MOATAMED, F., SCHINDLER, A., and PITT, C. G., 1985, The intracellular degradation of Poly(E caprolactone). Journal of Biomedical Material Research, 19, 437–444.
   PubMedGoogle Scholar
• WORTHWEIN, G., 1989, Dissertation, Munster. Affinitaten von Glukokortikoiden zum humanen Glukokortikoid rezeptor und Stabilität der Beclomethason ester in körperflüssigkeiten.
   Google Scholar